Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash from Investing Activities (2017 - 2026)

Denali Therapeutics has reported Cash from Investing Activities over the past 9 years, most recently at $20.8 million for Q4 2025.

  • Quarterly Cash from Investing Activities fell 87.94% to $20.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $255.3 million through Dec 2025, up 387.62% year-over-year, with the annual reading at $255.3 million for FY2025, 387.62% up from the prior year.
  • Cash from Investing Activities was $20.8 million for Q4 2025 at Denali Therapeutics, down from $57.8 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $172.2 million in Q4 2024 and troughed at -$453.2 million in Q1 2024.
  • The 5-year median for Cash from Investing Activities is $39.3 million (2025), against an average of $12.6 million.
  • Year-over-year, Cash from Investing Activities surged 554.45% in 2023 and then tumbled 388.8% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$40.8 million in 2021, then tumbled by 213.03% to -$127.6 million in 2022, then skyrocketed by 157.27% to $73.0 million in 2023, then surged by 135.75% to $172.2 million in 2024, then crashed by 87.94% to $20.8 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Cash from Investing Activities are $20.8 million (Q4 2025), $57.8 million (Q3 2025), and $157.9 million (Q2 2025).